Mejía-Olivares B, Rentería-Perea A, Martínez-Delgado IA

Language: Spanish
References: 10
Page: 39-42
PDF size: 702.12 Kb.

ABSTRACT

Castleman´s disease is a disorder characterized by reactive lymphoid hyperplasia and progressive growth of benign tumors of lymphoid tissue and increased predisposition to develop lymphoma. The real prevalence is unknown; it has been estimated at less than 1/100.000. Even this is a rare disease, it should be considered in the differential diagnosis of mediastinal tumors with increase uptake in the CT scan.

REFERENCES

1. Castilletti HJM, Vargas SDM, Martinez M, Rojas N. Enfermedad Castleman. A propósito de dos casos. Arch Venez Pueri Pediatr 2008;71:54-58.

2. Sarrot-Reynauld F. Castleman’s disease. Orphanet encyclopedia 2001;1-4.

3. Viveros ALM, Sánchez MJF. Enfermedad de Castleman. Reporte de un caso en adolescente. An Med Asoc Med Hosp ABC 2001;46:193-196.

4. Bonekamp D, Horton HM, Hruban RH, Fishman EK. Castleman disease: the great mimic. Radiographics 2011;31:1793-1807.

5. Rodríguez SH, Buchaca FE, Machado PI, Pérez RG, Pérez CD. Enfermedad de Castleman. Presentación de cinco casos. An Med Interna (Madrid) 2005;22:24-27.

6. Bucher P, Chassot G, Zufferey G, Ris F, Huber O, Morel P. Surgical management of abdominal and retroperitoneal Castleman’s disease. World J Surg Oncol 2005;3:1-9.

7. Sobrevilla-Calvo PJ, Avilés-Salas A, Cortés-Padilla DE, Rivas-Vera S. Características clinicopatológicas de la enfermedad de Castleman. Experiencia en el Instituto Nacional de Cancerología. Cir Ciruj 2009;77:187-192.

8. El-Osta HE, Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist 2011;16:497-451.

9. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989;74:1360-1367.

10. Nakazawa-Soken JS, Kazuyuki Yoshizaki. Up-regulation of hepcidin by interleukin-6 contributes to anemia of inflammation in multicentric Castleman’s disease. Mini Review 2012;32:99-106.